TRUFF (Rhelion Life Sciences) Liabilities-to-Assets : 0.23 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Rhelion Life Sciences Liabilities-to-Assets?

Rhelion Life Sciences TRUFF +1.60% Liabilities-to-Assets is 0.23 as of Mar. 2026. The stock has 3 warning signs investors should review.

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Rhelion Life Sciences's Total Liabilities for the quarter that ended in Mar. 2026 was $2.44 Mil. Rhelion Life Sciences's Total Assets for the quarter that ended in Mar. 2026 was $10.62 Mil. Therefore, Rhelion Life Sciences's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2026 was 0.23.

Rhelion Life Sciences  (OTCPK:TRUFF) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.

Rhelion Life Sciences Liabilities-to-Assets Related Terms

Rhelion Life Sciences Liabilities-to-Assets Historical Data

* Premium members only.

The historical data trend for Rhelion Life Sciences's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rhelion Life Sciences Liabilities-to-Assets Chart

Rhelion Life Sciences Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Liabilities-to-Assets
Get a 7-Day Free Trial 0.12 0.13 0.16 0.18 0.23

Rhelion Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.17 0.18 0.20 0.23

TRUFF vs ZTS: Liabilities-to-Assets Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Rhelion Life Sciences's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rhelion Life Sciences Liabilities-to-Assets vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Rhelion Life Sciences's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Rhelion Life Sciences's Liabilities-to-Assets falls into.


Rhelion Life Sciences Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Rhelion Life Sciences's Liabilities-to-Assets Ratio for the fiscal year that ended in Mar. 2026 is calculated as:

Liabilities-to-Assets (A: Mar. 2026 )=Total Liabilities/Total Assets
=2.441/10.62
=0.23

Rhelion Life Sciences's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2026 is calculated as

Liabilities-to-Assets (Q: Mar. 2026 )=Total Liabilities/Total Assets
=2.441/10.62
=0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Liabilities-to-Assets →
What does a Liabilities-to-Assets of 0.23 mean?
Rhelion Life Sciences (TRUFF) has a Liabilities-to-Assets of 0.23 as of Mar. 2026. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Rhelion Life Sciences and its competitors.
Is Rhelion Life Sciences' Liabilities-to-Assets too high?
Rhelion Life Sciences' current Liabilities-to-Assets is 0.23.
How does Rhelion Life Sciences' Liabilities-to-Assets compare to ZTS?
Rhelion Life Sciences' Liabilities-to-Assets of 0.23 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Drug Manufacturers company?
A good Liabilities-to-Assets depends on the Drug Manufacturers industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Rhelion Life Sciences and its competitors. Rhelion Life Sciences's current Liabilities-to-Assets is 0.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhelion Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Rhelion Life Sciences (TRUFF) is currently considered Fairly Valued. The stock's GF Value™ is $0.03, compared to a current price of $0.02 — trading 28.2% below its estimated fair value. The current Liabilities-to-Assets is 0.23. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Rhelion Life Sciences (TRUFF), the current Liabilities-to-Assets is 0.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rhelion Life Sciences Business Description

Other Exchanges 4YX:GermanyTRIP:Canada
Address 1 Adelaide Street East, Suite 801, Toronto, ON, CAN, M5C 2V9
Red Light Holland Corp is engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands. Its products include Microdosing Kit and Merch. Its revenue is comprised of sales of wholesale truffles, cannabis seeds, and other cannabis products and sales of microdose packs.